The two companies filed a New Drug Application on Jan. 9, 2009 and learned in November that the agency extended the review date of Horizant to Feb. 9 to perform a risk evaluationand mitigation plan for the drug.
The class labeling is based on FDA evaluation of all statin labels, entry of new interacting drugs on the market, and a review of clinical data and post marketing reports.